Table 1.

In vitro immunogenicity of TOP HLA-presented EOC antigens (MUC16, IDO1, LGALS1, KLK10, CRABP1/2) as well as antigens with additional HLA peptide presentation on normal tissues (MKI67, DDX5)

				Tissues with HLA peptide presentation of source antigen (%)			Tissues with HLA peptide presentation
HLA	Sequence	Protein	Positive/tested donors	EOC	OvN	Benign sources	EOC	OvN	Benign sources
A*01	STETSTVLY	MUC16	0/3	33/42 (79)	5/23 (22)	0/85 (0)	3	0	0
A*02	IITEVITRL	MUC16	3/10				1	0	0
A*02	KMISAIPTL	MUC16	4/6				3	0	0
A*03	SVLADLVTTK	MUC16	0/1				1	0	0
A*11	STSQEIHSATK	MUC16	2/6				1	0	0
A*11	GTSGTPVSK	MUC16	0/5				1	0	0
A*24	TYSEKTTLF	MUC16	3/3				5	1	0
A*24	QFITSTNTF	MUC16	1/2				1	0	0
A*24	AVTNVRTSI	MUC16	1/3				2	0	0
A*25	EVITSSRTTI	MUC16	1/1				2	0	0
A*25	EVISSRGTSM	MUC16	1/3				3	0	0
A*25	EVTSSGRTSI	MUC16	2/3				3	0	0
A*25	ETILTFHAF	MUC16	2/2				5	0	0
B*07	SPHPVTALL	MUC16	1/1				4	0	0
B*07	SPQNLRNTL	MUC16	2/3				4	0	0
B*07	TPGNRAISL	MUC16	5/5				6	1	0
B*07	SPLFQRSSL	MUC16	1/3				1	0	0
B*07	SPHPVTALL	MUC16	1/2				4	0	0
B*07	LPHSEITTL	MUC16	1/3				2	0	0
B*07	TPGGTRQSL	MUC16	0/3				7	3	0
B*07	SPSKAFASL	MUC16	3/3				9	2	0
B*07	VPRSAATTL	MUC16	2/3				3	0	0
B*15	SQGFSHSQM	MUC16	4/5				1	0	0
B*15	FQRQGQTAL	MUC16	1/6				1	0	0
B*18	TETEAIHVF	MUC16	1/1				4	0	0
B*27	ERSPVIQTL	MUC16	1/2				1	0	0
B*51	DPYKATSAV	MUC16	3/3				7	1	0
B*51	DALVLKTV	MUC16	1/3				5	0	0
A*03	RSYHLQIVTK	IDO1	1/1	12/42 (29)	4/23 (17)	0/85 (0)	5	2	0
A*11	RSYHLQIVTK	IDO1	1/1				5	2	0
A*24	RYMPPAHRNF	IDO1	4/4				2	0	0
B*07	NPKAFFSVL	IDO1	3/5				1	0	0
A*25	EVAPDAKSF	LGALS1	1/1	11/42 (26)	1/23 (4)	0/85 (0)	5	1	0
A*02	RTTEINFKV	CRABP1/2	1/2	15/42 (36)	0/23 (0)	0/85 (0)	9	0	0
A*02	RALAKLLPL	KLK10	2/2	9/42 (21)	0/23 (0)	0/85 (0)	7	0	0
A*11	SSKSQTEVPK	MKI 67	0/5	21/42 (50)	0/23 (0)	14/85 (16)	0	0	5
B*08	TPKEKAQAL	MKI 67	0/5				2	0	0
A*02	YLLPAIVHI	DDX 5	0/5	29/42 (69)	18/23 (78)	63/85 (74)	23	13	36